Search bioRxiv⌕ Search

Biology subjects

Whistler, J. L.

Publications and source records attributed to Whistler, J. L..

2 recordsLinked to original sources

Acute in vivo proximity labeling for membrane targeted proteomics in neuronal circuits

MOTIVATIONDespite the growing use of proximity labeling tools, there are limited techniques available to identify subcellularly localized proteins within targeted neuronal circuits on acute timescales in vivo. We engineered membrane targeted versions of the proximity labeling enzyme TurboID and validated their use for proteomic discovery in the mouse brain. We optimized an in vivo protocol to identify proteins in cell bodies and long range neuronal projections, and proteins differentially detected during acute drug labeling windows. SUMMARYA major goal within molecular systems neuroscience is to bridge the study of neuronal circuit function with changes in protein expression and localization in awake behaving animals. However, there are limited tools for capturing changes in subcellularly-defined proteomes within neuronal circuits during activity-gated timescales in vivo. Here, we engineered targeted versions of the proximity labeling enzyme TurboID, to tag proteins at the neuronal membrane during a user-delivered biotin injection. We optimized a labeling strategy that enables a one-to-two-hour labeling window and tagged proteins in medial prefrontal cortex (mPFC) cell bodies and corresponding axons in a downstream projection. We performed proteomics to identify proteins enriched in mPFC cell bodies and terminals, and upregulated in mPFC cell bodies following an acute cocaine injection. These advancements enable the detection of proteins at the subcellular level within short labeling windows, allowing identification of stimulus-specific proteomes in behaving mice.

neuroscience↗

Arrestin-3 agonism at D3 dopamine receptors defines a subclass of second generation antipsychotics that promotes drug tolerance

Second generation antipsychotics (SGAs) are front-line treatments for serious mental illness. Often, individual patients benefit only from some SGAs and not others. The mechanisms underlying this unpredictability in treatment efficacy remain unclear. All SGAs bind the D3 dopamine receptor (D3R) and are traditionally considered antagonists for dopamine receptor signaling. Here, we report that some clinically important SGAs function as arrestin-3 agonists at D3R, resulting in modulation of calcium channels localized to the site of action potential initiation in prefrontal cortex pyramidal neurons. We further show that chronic treatment with an arrestin-3 agonist-SGA, but not an antagonist-SGA, abolishes D3R function through post-endocytic receptor degradation by G-protein coupled receptor-associated sorting protein-1 (GASP1). These results implicate D3R-arrestin-3 signaling as a source of SGA variability, highlighting the importance of including arrestin-3 signaling in characterizations of drug action. Furthermore, they suggest that post-endocytic receptor trafficking that occurs during chronic SGA treatment may contribute to treatment efficacy.

neuroscience↗